[go: up one dir, main page]

WO2006138670A3 - Antibody complexes - Google Patents

Antibody complexes Download PDF

Info

Publication number
WO2006138670A3
WO2006138670A3 PCT/US2006/023659 US2006023659W WO2006138670A3 WO 2006138670 A3 WO2006138670 A3 WO 2006138670A3 US 2006023659 W US2006023659 W US 2006023659W WO 2006138670 A3 WO2006138670 A3 WO 2006138670A3
Authority
WO
WIPO (PCT)
Prior art keywords
complex
cell
ligands
hemopoietic
hemopoietic cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/023659
Other languages
French (fr)
Other versions
WO2006138670A2 (en
Inventor
Laurent Humeau
Brian Paszkiet
Franck Lemiale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VirxSys Corp
Original Assignee
VirxSys Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2005304670A external-priority patent/JP2006345852A/en
Application filed by VirxSys Corp filed Critical VirxSys Corp
Priority to CA002612355A priority Critical patent/CA2612355A1/en
Publication of WO2006138670A2 publication Critical patent/WO2006138670A2/en
Publication of WO2006138670A3 publication Critical patent/WO2006138670A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention is directed to a soluble complex of ligands that binds to surface molecules of hemopoietic cells and result in their activation or expansion. The complex may be used in the activation and/or expansion of hemopoietic cells, optionally in combination with their transduction. The complex of ligands bind at least two cell surface molecules, such as one that plays a role in cell-cell adhesion and one that may or may not activate or stimulate the cell to promote growth and/or proliferation after binding to a ligand. A complex of ligands that bind two hemopoietic cell stimulatory molecules is also provided. The invention further provides for the use of the complex to target vectors to hemopoietic cells.
PCT/US2006/023659 2005-06-16 2006-06-16 Antibody complexes Ceased WO2006138670A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002612355A CA2612355A1 (en) 2005-06-16 2006-06-16 Antibody complexes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69163105P 2005-06-16 2005-06-16
US60/691,631 2005-06-16
JP2005304670A JP2006345852A (en) 2005-06-16 2005-10-19 Antibody complex
JP2005-304670 2005-10-19

Publications (2)

Publication Number Publication Date
WO2006138670A2 WO2006138670A2 (en) 2006-12-28
WO2006138670A3 true WO2006138670A3 (en) 2007-05-03

Family

ID=37136223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/023659 Ceased WO2006138670A2 (en) 2005-06-16 2006-06-16 Antibody complexes

Country Status (2)

Country Link
CA (1) CA2612355A1 (en)
WO (1) WO2006138670A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296822B2 (en) 2005-12-08 2016-03-29 E.R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E
US9493564B2 (en) 2008-10-02 2016-11-15 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120040976A1 (en) * 2008-12-11 2012-02-16 Human Biomolecular Research Institute Small molecule immunomodulators for alzheimer's disease
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
AU2013361275B2 (en) 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
CN103966313B (en) * 2014-03-19 2017-01-11 新乡学院 Construction of pig peripheral bloodmononuclear lymphocytePD-L1 (programmed death-ligand1) recombinantplasmids, real-time gene abundance detection method and application of method
ES2808914T3 (en) 2014-09-04 2021-03-02 Stemcell Tech Inc Soluble antibody complexes for the activation and expansion of T lymphocytes or NK cells
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
SG11202004158QA (en) 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
RU2020126574A (en) * 2018-01-11 2022-02-11 Кэмилиэн Байосайнсиз, Инк. VECTORS ESCAPE FROM IMMUNE SURVEILLANCE AND THEIR APPLICATION IN GENOTHERAPY
CN111699200B (en) 2018-01-15 2023-05-26 南京传奇生物科技有限公司 Single domain antibodies against PD-1 and variants thereof
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
WO2024237744A1 (en) * 2023-05-18 2024-11-21 서울대학교산학협력단 Anti-cd40l/anti-cd28 bispecific antibody and use thereof
WO2025019077A1 (en) 2023-07-18 2025-01-23 Nanotein Technologies, Inc. Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US6197298B1 (en) * 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
EP1553168A2 (en) * 1993-06-04 2005-07-13 The United States of America as Represented by The Secretary of The Navy Methods for selectively stimulating proliferation of T cells
EP1736484A1 (en) * 2004-04-01 2006-12-27 Beijing ABT Genetic Engineering Technology Co., Ltd. An gene enginf; ering recombinant anti-cea, anti-cd3 and anti-cd28 single-chain tri-specific antibody

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US6197298B1 (en) * 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
EP1553168A2 (en) * 1993-06-04 2005-07-13 The United States of America as Represented by The Secretary of The Navy Methods for selectively stimulating proliferation of T cells
EP1736484A1 (en) * 2004-04-01 2006-12-27 Beijing ABT Genetic Engineering Technology Co., Ltd. An gene enginf; ering recombinant anti-cea, anti-cd3 and anti-cd28 single-chain tri-specific antibody

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JUNG G ET AL: "TARGET CELL-INDUCED T CELL ACTIVATION WITH BI- AND TRISPECIFIC ANTIBODY FRAGMENTS", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 21, 1 October 1991 (1991-10-01), pages 2431 - 2435, XP000647636, ISSN: 0014-2980 *
LANSDORP P M ET AL: "CYCLIC TETRAMOLECULAR COMPLEXES OF MONOCLONAL ANTIBODIES: A NEW TYPE OF CROSS-LINKING REAGENT", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 16, no. 6, 1986, pages 679 - 683, XP009077557, ISSN: 0014-2980 *
WILLEMS AN ET AL: "CD3 x CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation"; PUBLISHED ONLINE ON 13/5/2005", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 54, no. 11, November 2005 (2005-11-01), pages 1059 - 1071, XP002416093, ISSN: 0340-7004 *
WONG-STAAL F: "Ribozyme gene therapy for HIV infection intracellular immunization of lymphocytes and CD34+ cells with and anti-HIV-1 ribozyme gene", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 17, 1995, pages 363 - 368, XP002983146, ISSN: 0169-409X *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296822B2 (en) 2005-12-08 2016-03-29 E.R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E
US9493564B2 (en) 2008-10-02 2016-11-15 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins

Also Published As

Publication number Publication date
CA2612355A1 (en) 2006-12-28
WO2006138670A2 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
WO2006138670A3 (en) Antibody complexes
WO2007066109A8 (en) Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
WO2005087808A3 (en) Growth factor binding constructs materials and methods
EP2241331A3 (en) Novel anti-DC-SIGN antibodies
WO2005113601A8 (en) Antibodies and molecules derived therefrom that bind to steap-1 proteins
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2009004822A1 (en) ANTI-Muc17 ANTIBODY
EP2423226A3 (en) Antibody-based diagnostics and therapeutics
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
MY162624A (en) Antibodies directed to her-3 and uses thereof
MX2007008017A (en) Polypeptides that bind br3 and uses thereof.
EP2559705A3 (en) Anti-activin a antibodies and uses thereof
WO2009020964A3 (en) Anti-neublastin antibodies and uses thereof
WO2009063965A1 (en) Monoclonal antibody capable of binding to anexelekto, and use thereof
WO2009055074A8 (en) Erbb2 binding proteins and use thereof
WO2005017205A3 (en) Nucleic acid mapping using linear analysis
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
WO2008083326A3 (en) Targeting of ews-fli1 as anti-tumor therapy
WO2023230626A3 (en) Ph-selective anti-cd3 antibodies and use of the same
WO2006044650A3 (en) Competitive differential screening
WO2006116631A3 (en) Cancer specific pcna isoform binding antibodies and uses thereof
WO2007009018A3 (en) Il-6 binding proteins
EP2192132A3 (en) Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
WO2007026972A3 (en) Binding protein molecule
WO2000062074A8 (en) Use of 13c-nmr to detect binding

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2612355

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06773445

Country of ref document: EP

Kind code of ref document: A2